Savannah Hope Williams, OTD Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 224 North St, Cave City, AR 72521 Phone: 870-292-3214 |
Wendy Dozier, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 416 N Main St Ste I, Cave City, AR 72521 Phone: 870-283-6757 Fax: 870-277-0896 |
Alexandra Lee Vericker, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 401 S Main St, Cave City, AR 72521 Phone: 870-283-1034 |
Kayla Marie Qualls, MS, OTR/L Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 699 Arrowhead Ln., Cave City, AR 72521 Phone: 870-307-4736 |
Brooklyn Brinkley Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 711 N Main St, Cave City, AR 72521 Phone: 870-283-5391 |
News Archive
The new school year means new clothes, new classes, new teachers - and the same old misery due to sneezing and wheezing for children who have allergies or asthma. From the class hamster to dust mites residing in carpet to germs from cold and flu viruses, asthma and allergy triggers lurk throughout the classroom.
As part of the U.S. Food and Drug Administration's ongoing efforts to ensure that heparin for patients remains safe, the government today seized 11 lots of heparin from Celsus Laboratories Inc. in Cincinnati, Ohio.
President Obama is praising an emerging congressional deal to extend the 2% payroll tax cut through 2012, and said he wants to sign it into law as soon as possible. "For starters, I'm glad to see that Congress seems to be on the way to making progress on extending the payroll tax cut so that taxes don't go up on you and 160 million working Americans," Obama told employees of the Master Lock company in Milwaukee today.
Today, Lung Cancer Alliance highlighted a study, carried out by Ipsos MORI on behalf of The Global Lung Cancer Coalition. The study finds lung cancer patients are likely to suffer significant stigma due to the disease's link to smoking.
ChemoCentryx, Inc., today announced that it has identified a novel drug candidate targeting the chemoattractant receptor known as ChemR23. This investigational new drug, designated CCX832, is an orally-administered small molecule antagonist of ChemR23, an important player in inflammatory disease.
› Verified 9 days ago